- Home
- CAAP vs MRUS Comparison
CAAP vs MRUS Comparison
Compare CAAP & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAP | MRUS |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | Luxembourg | Netherlands |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 5.1B |
| IPO Year | 2018 | 2016 |
Fundamental Metrics
Financial Performance| Metric | CAAP | MRUS |
|---|---|---|
| Price | $25.69 | $96.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $24.60 | ★ $94.94 |
| AVG Volume (30 Days) | 165.5K | ★ 1.2M |
| Earning Date | 11-24-2025 | 10-31-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $1,872,934,000.00 | $56,606,000.00 |
| Revenue This Year | $3.24 | $56.08 |
| Revenue Next Year | $9.46 | N/A |
| P/E Ratio | $23.34 | ★ N/A |
| Revenue Growth | 25.19 | ★ 57.54 |
| 52 Week Low | $15.01 | $33.19 |
| 52 Week High | $26.97 | $97.14 |
Technical Indicators
Market Signals| Indicator | CAAP | MRUS |
|---|---|---|
| Relative Strength Index (RSI) | 61.39 | 72.01 |
| Support Level | $24.97 | $96.78 |
| Resistance Level | $26.25 | $97.14 |
| Average True Range (ATR) | 0.77 | 0.20 |
| MACD | -0.20 | -0.11 |
| Stochastic Oscillator | 40.45 | 83.19 |
Price Performance
Historical ComparisonAbout CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.